All major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen. raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed.
机构:
Calif Pacific Med Ctr, Inst Res, San Francisco Coordinating Ctr, San Francisco, CA 94143 USACalif Pacific Med Ctr, Inst Res, San Francisco Coordinating Ctr, San Francisco, CA 94143 USA
机构:
Christie Hosp, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England
Univ S Manchester Hosp, Genesis Breast Canc Prevent Ctr, Manchester M20 9LT, Lancs, EnglandChristie Hosp, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England